Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma by Vordermark, Dirk et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Hypofractionated stereotactic re-irradiation: treatment option in 
recurrent malignant glioma
Dirk Vordermark*1, Oliver Kölbl1, Klemens Ruprecht2, Giles H Vince3, 
Klaus Bratengeier1 and Michael Flentje1
Address: 1Dept. of Radiation Oncology, University of Würzburg, Germany, 2Dept. of Neurology, University of Würzburg, Germany and 3Dept. of 
Neurosurgery, University of Würzburg, Germany
Email: Dirk Vordermark* - vordermark_d@klinik.uni-wuerzburg.de; Oliver Kölbl - oliver.koelbl@klinik.uni-regensburg.de; 
Klemens Ruprecht - klemens.ruprecht@mail.uni-wuerzburg.de; Giles H Vince - gvince@gmx.de; Klaus Bratengeier - Bratengeie_K@klinik.uni-
wuerzburg.de; Michael Flentje - flentje_M@klinik.uni-wuerzburg.de
* Corresponding author    
Abstract
Background:  Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment
option in previously irradiated patients with recurrent malignant glioma. We analyzed the results
of HFSRT and prognostic factors in a single-institution series.
Methods: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma
on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT. The median interval
from post-operative radiotherapy to HFSRT was 19 (range 3–116) months, the median daily single
dose 5 (4–10) Gy, the median total dose 30 (20–30) Gy and the median planning target volume 15
(4–70) ml.
Results: The median overall survival (OS) was 9.3 (1.9-77.6+) months from the time of HFSRT,
15.4 months for grade III and 7.9 months for grade IV tumors (p = 0.029, log-rank test). Two
patients were alive at 34.6 and 77.6 months. OS was longer after a total dose of 30 Gy (11.1
months) than after total doses of <30 Gy (7.4 months; p = 0.051). Of five (26%) reoperations, none
was performed for presumed or histologically predominant radiation necrosis. Median time to
tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.
Conclusion: HFSRT with conservative total doses of no more than 30 Gy is safe and leads to
similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in
combination with other salvage treatment modalities, was associated with long-term survival.
Background
Despite intensive multi-modality treatment including
tumor resection, post-operative radiotherapy and fre-
quently adjuvant chemotherapy, the prognosis of malig-
nant glioma continues to be poor. Local recurrence,
occuring almost exclusively inside the high-dose volume
of post-operative radiotherapy [1], represents a major
therapeutic challenge. Re-irradiation as a salvage treat-
ment option is limited by the radiation tolerance of sur-
rounding normal brain tissue. In recent years, single-dose
radiosurgery, normofractionated and hypofractionated
stereotactic radiotherapy have been investigated as a
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single modality or in combination with chemotherapy [2-
8]. Re-irradiation appeared to be associated with accepta-
ble toxicity when certain treatment volume and dose lim-
its were respected. Median survival in these series was
between 7 and 13 months from the time of salvage radio-
therapy suggesting a therapeutic benefit in selected patient
groups.
Since published data on hypofractionated stereotactic
radiotherapy as a sole modality in recurrent malignant gli-
oma are limited [4,5,8], we now analyzed the results of
such treatment in 19 consecutive patients treated at a sin-
gle institution.
Methods
Patients
Between 1997 and 2003, 19 patients were treated with
hypofractionated stereotactic radiotherapy (HFSRT) for
recurrent malignant glioma at the University of Würzburg,
Germany. The patient characteristics are summarized in
Table 1. All patients had received previous involved-field
radiotherapy with 45 to 61 Gy and 94% of patients had
been pretreated with chemotherapy, most often nimus-
tine (ACNU) and teniposide, a combination protocol
favored by the Neuro-Oncology Working Group of the
German Cancer Society [9].
Treatment technique
HFSRT was performed non-invasively using a commer-
cially available relocatable mask system as previously
described [10]. For planning CT, 3 mm scans of the brain
were obtained after administration of an i. v. contrast
agent. Treatment planning was performed using Helax
TMS (Nucletron, Veenendal, Netherlands) software. For
planning target volume (PTV) definition, a margin of 1 to
3 mm around the contrast-enhancing volume was used.
Depending on the shape of the PTV, treatment plans were
created containing multiple non-coplanar arcs, multiple
non-coplanar fixed fields or combinations of both. The
treatment plans were normalized to 100% at the isocenter
Table 1: Clinical characteristics of n = 19 consecutive patients treated with hypofractionated stereotactic radiotherapy (HFSRT) for 
recurrent malignant glioma.
median age (range) at time of HFSRT 50 years (11–74 years)
male / female 8 (42%)/11(58%)
median Karnofsky performance score at time of HFSRT (range) 90 (60–90)
initial histology
astrocytoma II° 3 (16%)
pure anaplastic astrocytoma III° 4 (21%)
anaplastic oligoastrocytoma or oligodendroglioma III° 3 (16%)
glioblastoma multiforme IV° 9 (47%)
most recent histology before HFSRT
anaplastic astrocytoma III° 5 (26%)
glioblastoma multiforme IV° 14 (74%)
initial surgical procedure
resection 15 (79%)
biopsy 4 (21%)
post-operative radiotherapy
1.8–2.0 Gy daily (total dose 54 to 61 Gy) 12 (63%)
3 Gy daily (total dose 45 Gy) 2 (11%)
2 × 1.8 Gy daily (total dose 54 Gy) 5 (26%)
salvage surgery before HFSRT 12 (63%)
adjuvant or salvage chemotherapy before HFSRT
nimustine / teniposide 12 (63%)
temozolomide 5 (26%)
other 1 (5%)
median interval post-OP radiotherapy to HFSRT (range) 19 months (3–116 months)BMC Cancer 2005, 5:55 http://www.biomedcentral.com/1471-2407/5/55
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and prescribed to a median isodose of 80% (range 70 to
90%), enclosing the PTV. Details of treatment planning
and dose prescription are given in Table 2.
Immediately before the first treatment session, CT simula-
tion was performed as described [10]. Briefly, the iso-
center position was verified with regard to bony and
parenchymal landmarks and to the contrast enhancing
tumor and positioning errors were corrected after attach-
ing the mask system to the treatment table. Treatment was
delivered from a Philips SL 75/20 or Siemens Primus lin-
ear accelerator (6 MV or 8 MV photons, respectively)
equipped with a manual micro-multileaf collimator. Sub-
sequent CT simulations were performed at the discretion
of the treating physician depending on the setup error
determined at time of the first fraction. HFSRT treatment
was performed five days per week. During the HFSRT
series, patients were maintained on their previous corti-
costeroid dose or corticosteroids were started. Daily doses
ranged between 32 mg of prednisolone and 40 mg of
dexamethasone.
Statistics
The main endpoint of this study was overall survival (OS)
from the time of HFSRT. Kaplan-Meier survival curves
were calculated for these intervals considering death as an
event and patients alive at last follow-up as censored. Sub-
groups were compared using the log-rank test. Statistical
analysis was performed with Statistica 6.1 software (Tulsa,
OK, USA). Overall survival from initial diagnosis and time
to tumor progression were considered as secondary end-
points. For the analysis of time to recurrence, neuroradio-
logical diagnoses of follow-up CT and MRI scans were
used. Imaging was routinely reviewed by an interdiscipli-
nary tumor board which based its recommendations on
these studies.
Results
HFSRT was well tolerated and no acute neurotoxicity or
deterioration in the general health status was observed.
Five of 19 patients were reoperated after HFSRT. In three
of these, resection was performed for tumor progression
on imaging. Histology showed tumor only in two of these
cases and predominant tumor with necrosis in one case.
In two patients, Ommaya reservoirs were implanted. Thir-
teen patients received further chemotherapy after HFSRT.
Temozolomide was used in six patients, nimustine / teni-
poside in four and other multi-agent protocols in three.
For the whole group of n = 19 patients with recurrent
malignant glioma, the median overall survival from the
time of HFSRT was 9.3 months (range 1.9 to 77.6+
months; Fig. 1). At the time of analysis, two patients were
alive at 34.6 months and 77.6 months. One-year and two-
year survival rates were 26% and 16%, respectively.
Overall survival from time of HFSRT for subgroups is
shown in Table 3.
WHO grading, both that determined at initial diagnosis of
glioma and the most recent before HFSRT, had a signifi-
cant impact on survival. Patients with a most recent
histopathology of a grade III glioma had a median overall
Table 2: Treatment details of hypofractionated stereotactic 
radiotherapy (HFSRT) in n = 19 consecutive patients with 
recurrent malignant glioma.
Median planning target volume (range) 15 ml (4–70 ml)
Median prescription isodose (range) 80% (70–90%)
Median single dose (range) 5 Gy (4–10 Gy)
Median total dose (range) 30 Gy (20–30 Gy)
Fractionation schedules
5 × 4 Gy 2 (11%)
4 × 5 Gy 5 (26%)
6 × 5 Gy 6 (32%)
5 × 6 Gy 5 (26%)
2 × 10 Gy 1 (5%)
HFSRT technique
multiple non-coplanar arcs 5 (26%)
multiple non-coplanar fixed fields 11 (58%)
combination arcs / fixed fields 3 (16%)
median field no. (range) 5( 3 – 8 )
Overall survival of n = 19 patients with recurrent malignant  glioma treated with hypofractionated stereotactic radiother- apy (HFSRT), from the time of re-irradiation Figure 1
Overall survival of n = 19 patients with recurrent malignant 
glioma treated with hypofractionated stereotactic radiother-
apy (HFSRT), from the time of re-irradiation.
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survival from the time of HFSRT of 15.4 (1.9 to 77.6)
months, those with grade IV tumors of 7.9 (4.2 to 38.8)
months (p = 0.029, log-rank test; Fig. 2). A trend toward a
beneficial effect of higher total doses (30 Gy vs. <30 Gy)
on overall survival was observed (p = 0.051; Table 3, Fig.
3). Median overall survival from the first histological diag-
nosis of glioma (of any grade) was 40.8 months (12.9 to
135 months). Respective median overall survival times
from first diagnosis by initial histological grade were
134.7 (64.5 to 135) months for WHO grade II, 57 (30.8
to 119.4+) months for grade III and 26 (12.9 to 40.8)
months for grade IV tumors.
Information on follow-up imaging was available in 15
patients. Tumor progression was first diagnosed on MRI
in 11 cases and on CT in four cases. The median interval
between HFSRT and documented tumor progression was
4.9 months (1.3 to 37.3 months) in the overall group and
Table 3: Median overall survival from the time of hypofractionated stereotactic radiotherapy (HFSRT) in subgroups of patients with 
recurrent malignant glioma.
n median (range) overall survival (months) p
WHO grade (initial histopathology)
II or III 10 13.5 (1.9–77.6) 0.036
IV 9 7.4 (4.2–10.8)
WHO grade (most recent before HFSRT)
III 5 15.4 (1.9–77.6) 0.029
IV 14 7.9 (4.2–38.8)
initial surgical procedure
biopsy 15 9.3 (4.2–77.6) 0.89
resection 4 9.2 (1.9–34.6)
chemotherapy before HFSRT
yes 13 9.3 (1.9–77.6) 0.76
no 6 8.9 (7.3–15.4)
reoperation before HFSRT
yes 12 8.4 (1.9–77.6) 0.93
no 7 9.3 (5.6–34.6)
age at time of HFSRT
< 50 years 11 11.9 (1.9–77.6) 0.14
> 50 years 8 8.9 (5.0–11.1)
Karnofsky performance score at time of HFSRT
≥  90 14 7.9 (4.2–77.6) 0.80
< 90 5 11.9 (1.9–15.4)
planning target volume (ml)
< 15 ml 9 9.3 (5.2–38.8) 0.59
> 15 ml 10 7.4 (1.9–77.6)
interval first RT series to HFSRT
> 20 months 9 7.4 (1.9–77.6) 0.90
< 20 months 10 9.3 (5.6–38.8)
total HFSRT dose
30 Gy 11 11.1 (1.9–77.6) 0.051
< 30 Gy 8 7.4 (4.2–11.9)
chemotherapy after HFSRT
yes 13 9.3 (1.9–77.6) 0.27
no 6 8.9 (4.2–11.1)BMC Cancer 2005, 5:55 http://www.biomedcentral.com/1471-2407/5/55
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7.6 months (3.9 to 37.3 months) and 4.6 months (1.3 to
29.5 months) in the subgroups with a most recent histol-
ogy of grade III astrocytoma and glioblastoma,
respectively.
Survival times from initial diagnosis for the two living
patients were 49.7 and 119.4 months. The patient alive at
119.4 months (77.6 months from HFSRT) is a child first
treated with HFSRT at the age of eleven for a fourth recur-
rence of an anaplastic astrocytoma after multiple
resections, fractionated radiotherapy and intensive multi-
agent chemotherapy. After further adjuvant chemother-
apy, this patient recurred 37 months after HFSRT and has
since been treated with another resection, a second series
of HFSRT (49 months after the first HFSRT) to a volume
adjacent to the initial HFSRT region (7 × 5 Gy, 80% isod-
ose) and implantation of BCNU polymers. The most
recent MRI in this patient showed no evidence of tumor
recurrence. This patient was the only pediatric case
included in the present analysis. The patient alive at 49.7
months from initial diagnosis (34.6 months from HFSRT)
was first treated for anaplastic astrocytoma at 34 years
with biopsy, involved-field radiotherapy and multi-agent
chemotherapy. Twelve months after the first radiotherapy
series, HFSRT and sequential temozolomide were given
for tumor recurrence.
Discussion
Local recurrence of malignant glioma pretreated with
resection, post-operative radiotherapy and frequently
with adjuvant chemotherapy is a common problem in
clinical practice. Reoperation, re-irradiation and systemic
or intratumoral chemotherapy are among the therapeutic
options available in this situation. Only the implantation
of BCNU polymers at the time of reoperation is supported
by randomized trial data, having been shown to be
superior to re-resection alone [11]. The benefit of other
treatments needs to be evaluated based on phase II data
and retrospective analyses which both are prone to bias by
patient selection for salvage treatment. A recent large ret-
rospective investigation analyzed the benefit of salvage
treatment in patients with glioblastoma multiforme [12].
The authors found that the first, mostly chemotherapeu-
tic, reintervention in this patient group was associated
with a doubling in median overall survival from 26 to
61.5 weeks, although selection effects in this series can not
be excluded.
Prolongation of survival in recurrent malignant glioma
has not been convincingly shown for either re-resection or
re-irradiation by interstitial brachytherapy, single-dose
radiosurgery or fractionated radiotherapy [13].
Hypofractionated stereotactic radiotherapy (HFSRT) has
been proposed as a combination of high-precision treat-
ment with small margins and maximum sparing of nor-
mal brain tissue, non-invasive technique and short
treatment duration using single fraction doses of 3 Gy to
9 Gy (Table 4).
Overall survival from the time of re-irradiation of n = 19  patients with recurrent malignant glioma treated with hypof- ractionated stereotactic radiotherapy (HFSRT), by WHO  grade (most recent histopathology before HFSRT) Figure 2
Overall survival from the time of re-irradiation of n = 19 
patients with recurrent malignant glioma treated with hypof-
ractionated stereotactic radiotherapy (HFSRT), by WHO 
grade (most recent histopathology before HFSRT).
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Overall survival from the time of re-irradiation of n = 19  patients with recurrent malignant glioma treated with hypof- ractionated stereotactic radiotherapy (HFSRT), by total dose Figure 3
Overall survival from the time of re-irradiation of n = 19 
patients with recurrent malignant glioma treated with hypof-
ractionated stereotactic radiotherapy (HFSRT), by total 
dose.
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In the present single-institution series of patients with
recurrent malignant glioma, median survival times from
the time of HFSRT of 9.3 months (most recent histology
grade III 15.4 months, grade IV 7.9 months) were
achieved. In published series of HFSRT, applied either as
a single modality or in combination with chemotherapy,
median overall survival ranged between 7 and 12.7
months (Table 4). Comparability between these series is
limited by differences in patient selection and treatment
concept. The median total dose of 30 Gy in 5-Gy fractions
in the present series is close to the limit of 35 Gy which is
thought to be applicable in pre-irradiated patients with
acceptable toxicity [4]. However, a total dose of 20 Gy in
4-Gy or 5-Gy fractions, as used in about one third of
patients, may be regarded as too low based on recent liter-
ature data [4]. Indeed, a trend toward longer survival with
total doses of at least 30 Gy was observed (Table 3, Fig.
1C). The finding that no patient in the present series had
to be reoperated for symptomatic radiation necrosis also
suggests that the dose schedules prescribed were rather
conservative. Other potential prognostic factors such as
age, Karnofsky performance score or tumor size (planning
target volume) were not significant predictors of survival
in the present series, possibly due to the limited patient
number.
It must be noted that in many patients HFSRT was one ele-
ment of salvage therapy and further chemotherapy or sur-
gical interventions were performed in 68% and 26% of
patients, respectively. In the patients with available imag-
ing information, the median time from HFSRT to tumor
progression was approximately five months which may be
regarded as an approximation of the lifetime gained by
HFSRT in these highly selected patients. In the patient
with the longest survival time of 77.6+ months after re-
irradiation, a second HFSRT series was performed as well
as multiple other treatments, highlighting the benefit of
aggressive multi-modality treatment in individual
patients. The longest survival time in glioblastoma was
38.8 months from HFSRT, indicating that even in grade IV
tumors single patients may survive much longer than
expected.
Data from the present series and published reports suggest
that efficacy and toxicity are favorable compared to single-
dose radiosurgery and the invasive modality of interstitial
brachytherapy. While radiosurgery resulted in median
Table 4: Overview of published results on hypofractionated stereotactic radiotherapy (HFSRT) in patients with recurrent malignant 
glioma (RT: radiotherapy).
authors patient 
number
single dose 
(Gy)
total dose 
(Gy)
median 
tumor 
volume (ml)
chemo-
therapy
overall 
survival 
(median)
surgery for 
toxicity
prognostic 
factors
comment
Shepherd et 
al., 1997 [4]
29 ("high-
grade 
astrocy-
toma")
5 (daily) 20–50 24 (3–93) -- 10.7 months 6% initial low-
grade histology 
associated with 
longer survival
36% steroid 
dependent 
toxicity 
(increased risk 
>40 Gy)
Glass et al., 
1997 [6]
20 (7 grade 
III, 13 grade 
IV)
3.5–6 (twice 
/ week)
35–42 14 (2–122) cisplatin 40 mg/
m2 weekly
12.7 months 15% pre-
dominant 
necrosis on 
re-operation
-- 40% treated 
within 10 weeks 
of first RT series 
for ("potential") 
progression
Hudes et al., 
1999 [5]
19 (glio-
blastoma)
3–3.5 (daily) 24–35 13 (1–48) -- 10.5 months 0% "minor 
response" on 
imaging 
associated with 
≥ 30 Gy and 
≤ 20 ml
recurrent or 
persistent 
tumors treated, 
median interval 
between 
completion of 
RT and HFSRT 
only 3.1 months
Lederman et 
al., 2000 [7]
88 (glio-
blastoma)
4–9 
(weekly)
18–36 32.7 (2–150) paclitaxel 120 
mg/m2 (median) 
weekly
7 months 8% necrosis 
only at re-
operation
volume ≥ 30 ml 
associated with 
longer survival
median time 
from diagnosis 
to HFSRT only 
6.5 months
Voynov et 
al., 2002 [8]
10 (5 WHO 
grade III, 5 
grade IV)
5 30 34.7 -- 10.1 months ? -- stereotactic 
intensity-
modulated 
radiotherapy 
(IMRT) used
present 
series
19 (5 WHO 
grade III, 14 
grade IV)
4–10 (daily) 20–30 15 (4–70) -- 9.3 months 0% WHO grade IV 
and <30 Gy 
associated with 
short survival
median interval 
post-OP RT to 
HFSRT 19 
monthsBMC Cancer 2005, 5:55 http://www.biomedcentral.com/1471-2407/5/55
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overall survival times of 26 to 50 weeks and reoperation
rates of 0 to 22%, median overall survival of 47 weeks and
reoperation in 41 to 44% (with about 5% of patients
showing radionecrosis only) were reported for interstitial
brachytherapy [13]. In a recent review of re-irradiation,
HFSRT was favored as radiotherapy modality and the fol-
lowing criteria for the application of HFSRT were recom-
mended [14]: good general status (WHO 0–1), at least
one year disease-free interval, initial grade II or III histol-
ogy and maximal tumor diameter 3 cm.
While such criteria may identify patients with the greatest
benefit from HFSRT, salvage treatment decisions in recur-
rent malignant glioma will remain highly individualized.
Given the low toxicity of the method, HFSRT may be
offered to patients in good general condition with tumor
recurrences of limited volume.
Conclusion
HFSRT with moderate total doses of no more than 30 Gy
is safe and leads to similar OS times as more aggressive
treatment schemes. In individual patients, HFSRT in
combination with other salvage treatment modalities, can
be associated with long-term survival.
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